Platform
Thousands of small molecule drugs have been derisked as safe in cancer clinical trials, but then did not demonstrate a general benefit for unselected cancer patients. Many of these drugs are dependent on the driver biology and work unusually well in specific genetic contexts. Our platform tests all of these contexts in parallel against the drug biology to identify where the drug will work.
OncoSLX™ Platform
We see the full potential of small molecules as genetically targeted therapies
We deploy a highly optimized pooled CRISPR screening approach to identify synergies between cancer driver perturbations and potential small molecule drugs. Unlike traditional synthetic lethality screening that completely removes drug targets from cells, pharmacogenetics allows us to capture the full spectrum of drug biology, including the many ways in which drugs modulate target function.
Validating OncoSLX Predictions with Real-World Data
In retrospective analyses of standard-of-care agents, OncoSLX identified dozens of novel pharmacogenetic relationships, with the vast majority confirmed to have statistically significant survival benefit in real‑world datasets.
NSCLC patients with sensitizing mutation identified by OncoSLX have significantly better outcomes when treated with OncoSLX identified drug. Effect is apparent in this mutational background (Cox proportional hazards analysis).
